| Name | Title | Contact Details |
|---|
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
Endotec Inc is a South Orange, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medisafe® is the leading Personalized Medication Management Platform helping patients stay on top of all their medications. Way more than a pill organizer (although it`s that, too), Medisafe makes it easy to adhere to the most complicated medication schedule, so wondering, “Did I take this already?” is a thing of the past. But that`s just the beginning. Medisafe connects users to their family (and soon, their doctors) for support, encouragement and expertise. It learns about each user`s unique situation, so it can deliver custom notifications for appointments and refills, medication updates, personalized health recommendations and discounts to help you stay organized, informed and on budget. And it tracks progress correlated with measurements like blood pressure and glucose levels to show the direct health benefit of taking meds as prescribed. By addressing all the major root causes for failing to take medications as prescribed, Medisafe improves patient satisfaction and quality of care and eliminates admissions and outpatient visits resulting from incorrect or missed doses. Medisafe arms providers and payers with information about patient compliance and related behaviors, so they can focus on the most pressing situations at any time. Understanding which patients are most at risk (and threatening to add avoidable strain to an overburdened healthcare system) helps all stakeholders in the care continuum use limited time and resources as efficiently as possible. Medisafe currently has more than 7 million users across iOS and Android smartphones and tablets, who have recorded over 4 billion medication doses taken correctly. Nearly 250,000 users have rated the app an average of 4.6 out of 5 stars in the iTunes and Google Play app stores.
lcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx`s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMet for Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic market. Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians support the team. In September 2013, Elcelyx announced the formation of NaZura BioHealth Inc, a separate company established to focus on the development on non-NewMet assets.
Apollo MarCom is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.